Two real-world studies (DESCRIBE I [N = 331] and DESCRIBE II [N = 271]) evaluated the treatment patterns and clinical outcomes of patients with BRAF V600–mutant unresectable or metastatic melanoma treated with either dab monotherapy or dab + tram combination therapy enrolled in the Named Patient Program (NPP). This evidence concerns the gene BRAF and metastatic melanoma.